# A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome

> **NCT04129164** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 183 (actual)

## Conditions studied

- Sjögren's Syndrome

## Interventions

- **DRUG:** VIB4920
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04129164
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-09
- **Primary completion:** 2022-09-01
- **Final completion:** 2023-03-10
- **Target enrollment:** 183 (ACTUAL)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04129164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04129164, "A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04129164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*